Activity Overview
The management of small cell lung cancer has been transformed with the introduction of novel immunotherapeutic strategies into the standard of care. In this online activity, 2 expert faculty in the management of small cell lung cancer discuss the emergence and evolution of DLL3-directed therapies, including concepts like data supporting the use of these agents, ongoing clinical trials, and management of key adverse events.
Target Audience
This educational activity is directed toward oncologists, pathologists, and other physicians interested in the treatment of SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the mechanism of action of DLL3-targeting bispecific and trispecific T-cell engagers to treat SCLC
- Discuss how recent trial evidence of DLL3-targeting therapies may inform future treatment selections for patients with SCLC
- Discuss strategies to mitigate risk, identify, and manage toxicities associated with DLL3-targeted therapies in patients with SCLC
Jacob Sands, MD
Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Jazz Pharmaceuticals, Gilead, Merck, Novartis, Pfizer, Sanofi, Medtronic; Grant/Research Funding: Amgen, Harpoon, Novartis
Anne Chiang, MD, PhD
Associate Professor, Section of Thoracic Oncology'
Yale School of Medicine
Associate Cancer Center Director, Clinical Initiatives
Yale Cancer Center
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Fosun, Genentech, Janssen, Jazz, Zai Lab; Grant/Research Funding: Amgen, AbbVie, AstraZeneca, Bristol Myers Squibb, GNE, Zai Lab
Disclosures/Disclaimers
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here